NuCana PLC Total Current Liabilities Over Time
| NCNA Stock | USD 1.26 0.03 2.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NuCana PLC Performance and NuCana PLC Correlation. NuCana |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NuCana PLC. If investors know NuCana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NuCana PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.67) | Return On Assets (0.68) | Return On Equity (1.81) |
The market value of NuCana PLC is measured differently than its book value, which is the value of NuCana that is recorded on the company's balance sheet. Investors also form their own opinion of NuCana PLC's value that differs from its market value or its book value, called intrinsic value, which is NuCana PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NuCana PLC's market value can be influenced by many factors that don't directly affect NuCana PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NuCana PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if NuCana PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NuCana PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare NuCana PLC and related stocks such as Effector Therapeutics, Virios Therapeutics Llc, and Zura Bio Limited Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 14.8 M | 20.3 M | 12.9 M |
| ZVSA | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 13.6 M | 8.2 M | 10.2 M | 10.9 M |
| CDTX | 116 K | 116 K | 116 K | 116 K | 3.2 M | 6 M | 8.9 M | 12.1 M | 19.9 M | 30.2 M | 38.6 M | 34 M | 30 M | 67.4 M | 70.8 M |
| SLN | 301 K | 1.3 M | 959 K | 1.7 M | 2 M | 1.1 M | 1.6 M | 2.7 M | 3.8 M | 9.7 M | 25.6 M | 15.2 M | 21.9 M | 17.8 M | 18.7 M |
| APLT | 993 K | 993 K | 993 K | 993 K | 993 K | 993 K | 993 K | 993 K | 4.4 M | 14.1 M | 21.2 M | 26.5 M | 33.4 M | 71.2 M | 74.7 M |
| CTMX | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 11.2 M | 15.7 M | 35.8 M | 61.1 M | 97.9 M | 85.6 M | 100.9 M | 106.3 M | 152.6 M | 155.9 M | 82.7 M |
| RANI | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 5.3 M | 2.6 M | 4.8 M | 8 M | 5.3 M |
| VINC | 44 K | 44 K | 44 K | 44 K | 44 K | 44 K | 44 K | 44 K | 44 K | 44 K | 5.5 M | 13.9 M | 9.2 M | 5.6 M | 7.5 M |
| TNYA | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 5 M | 21.8 M | 24.2 M | 22.7 M | 17.1 M |
| CRVS | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 3.1 M | 7.3 M | 9.9 M | 7.9 M | 12.5 M | 13.4 M | 12.3 M | 12.1 M | 6.9 M | 9.7 M |
| ALXO | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 5 M | 6.2 M | 15.3 M | 28.3 M | 36 M | 37.8 M |
| MREO | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 3.2 M | 9.6 M | 16.2 M | 29.9 M | 8.6 M | 12.5 M | 24.7 M | 9.5 M | 14.3 M |
| ABOS | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 6.4 M | 5.1 M | 7.8 M | 13 M | 7.4 M |
| DAWN | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 8.7 M | 16.6 M | 29.5 M | 31 M |
| INZY | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 3.2 M | 10 M | 11.6 M | 14.7 M | 14.7 M | 10.4 M |
NuCana PLC and related stocks such as Effector Therapeutics, Virios Therapeutics Llc, and Zura Bio Limited Total Current Liabilities description
Total Current Liabilities is an item on NuCana PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NuCana PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
Check out NuCana PLC Performance and NuCana PLC Correlation. For information on how to trade NuCana Stock refer to our How to Trade NuCana Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
NuCana PLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.